ストックスクリーナーアプリを入手
2.14
3.17%
-0.07
アフターアワーズ：
2.13
-0.01
-0.47%
前日終値:
$2.21
開ける：
$2.21
24時間の取引高:
110.09K
Relative Volume:
0.46
時価総額：
$92.72M
収益：
$2.70M
当期純損益:
$5.53M
株価収益率:
19.45
EPS:
0.11
ネットキャッシュフロー:
$-10.55M
1週間 パフォーマンス:
-8.55%
1か月 パフォーマンス:
+2.39%
6か月 パフォーマンス:
-12.30%
1年 パフォーマンス:
-26.71%
1日の値動き範囲:
$2.08
$2.2288
1週間の範囲:
$2.08
$2.404
52週間の値動き範囲:
$1.9929
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
名前
Oramed Pharmaceuticals Inc
セクター
電話
646-844-1164
住所
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
ORMP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.14 | 92.72M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-12 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-09 | 開始されました | National Securities | Buy |
| 2020-12-03 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-11 | 開始されました | Aegis Capital | Buy |
| 2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-12-11 | 再開されました | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 繰り返されました | FBR Capital | Outperform |
| 2015-12-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-11-19 | 開始されました | FBR Capital | Outperform |
| 2015-04-13 | 再開されました | MLV & Co | Buy |
| 2014-01-30 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-08 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-08 | 開始されました | MLV & Co | Buy |
| 2013-12-03 | 開始されました | Aegis Capital | Buy |
すべてを表示
Oramed Pharmaceuticals Inc (ORMP) 最新ニュース
Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com
Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal
Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle
AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire
Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com
Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire
ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa
ORMP stock touches 52-week low at $2 amid market challenges - Investing.com
Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0% - Armenian Reporter
OraMed Enters Global Licensing Deal for Lidocaine Product By Investing.com - Investing.com Australia
Oramed Pharmaceuticals (ORMP) to Release Quarterly Earnings on Wednesday - MarketBeat
OraMed Enters Global Licensing Deal for Lidocaine Product - Investing.com India
Rep. Brad Knott Sells Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares - MarketBeat
Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock - Benzinga
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to Sell Rating by StockNews.com - MarketBeat
227,239 Shares in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Acquired by Peapod Lane Capital LLC - MarketBeat
Oramed announces spinoff of protein drug technology - MSN
OraTech to pioneer oral insulin with $75 million investment - MSN
Oramed Pharmaceuticals : Ancillary Agreement Completion Protocol and Supplemental Agreement - Marketscreener.com
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St
Oramed Pharm Amends Joint Venture for OraTech Launch - TipRanks
Oramed (ORMP) Stock Skyrockets Amid JV Development Plans - Stocks Telegraph
OraTech to pioneer oral insulin with $75 million investment By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise - Marketscreener.com
Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology - Contract Pharma
Oramed stock soars on spinoff plans (ORMP:NASDAQ) - Seeking Alpha
Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin -February 11, 2025 at 09:17 am EST - Marketscreener.com
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PR Newswire
Charting the Course: Viking Therapeutics Inc’s VKTX Stock Prospects - The InvestChronicle
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below Two Hundred Day Moving Average – Here’s Why - Defense World
Oramed Pharmaceuticals Extends Maturity Date of Senior Secured Promissory Note in Recent Amendment - Defense World
Oramed Pharmaceuticals extends loan maturity, acquires Scilex shares - Investing.com
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - The Manila Times
Scilex Holding Company Announces Extension of the Maturity - GlobeNewswire
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Decrease in Short Interest - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to “Hold” at StockNews.com - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Raised to Hold at StockNews.com - MarketBeat
Oramed Pharmaceuticals Reports Deferral and Consent Agreement for Tranche B Senior Secured Convertible Note - Defense World
Oramed Pharmaceuticals Inc (ORMP) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):